Assembly Falls Well Short In Attempt At Finite HBV Therapy
Executive Summary
Biotech tried to show that a core inhibitor combined with standard hepatitis B therapy could yield lasting benefit after treatment. Vebicorvir will continue to be studied as a chronic treatment in HBV.
You may also be interested in...
Assembly Looks To Quickly Move Past ABI-H2158 Discontinuation
The company’s triple-combination studies with vebicorvir and next-generation core inhibitor programs may hold more promise in hepatitis B.
In Hep B, Functional Cure Likely Means Two-Part Combination Process
While current HBV drugs work well to suppress the virus, combination success in HIV and HCV is leading biopharmas to seek a multi-part approach to suppressing and clearing the virus, with limited-term therapy.
Asia Deal Watch: Hansoh Teams Up With OliX On SIRNA Therapies
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.